Heart Failure Clinical Trial
Official title:
CardioFiT™ for Heart Failure - Safety and Efficacy Study Protocol
Verified date | March 2011 |
Source | BioControl Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ministry of Health |
Study type | Interventional |
Congestive Heart Failure is the result of a number of diseases affecting the heart, causing
the heart's failure to properly meet the body demands for blood circulation. In spite of
advances in drug therapy, it remains a significant public health problem.
Pharmacologic antagonism of the beta-adrenergic receptors shifting the autonomic balance in
the direction of greater vagal influence is a well-proven treatment for heart failure
patients, although there are patients who cannot tolerate, or only partially benefit from
such a treatment.
It has been proven in the past and well established that parasympathetic nerve stimulation
can slow the rate of the heart and reduce the workload of the heart. Therefore, the
potential benefit of vagus nerve stimulation, hence parasympathetic activation, for
treatment of heart failure is substantial.
In this study, the safety and efficacy of a new vagus nerve stimulating system will be
evaluated. This study will compare whether the new device improves Heart Failure parameters
in Class II - III Heart Failure patients.
Status | Completed |
Enrollment | 32 |
Est. completion date | February 2010 |
Est. primary completion date | February 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. The patient is in chronic heart failure, NYHA II-III. The patient may have been previously in class IV but must be in class II or III for three or more months prior to study entry; 2. Age between 18 and 75 years; 3. The patient is a male or postmenopausal female. Females of childbearing age may be included if pregnancy is excluded and acceptable contraception measures are used; 4. Patient must sign an approved informed consent form. Patient agrees to attend all follow-up evaluations; 5. Patient should be in sinus rhythm. Average 24-hour heart rate is between 60 and 110 b/min in a recorded 24-h Holter measurement; 6. Patient should be in optimal medical treatment with no change in treatment in the previous 3 months with the exception of diuretics; 7. Left ventricular ejection fraction estimated by echocardiography, cardiac angiography, radionuclide study, or other accepted mode of evaluation, is no more than 35%; 8. Patient is physically capable and willing to perform repeated physically demanding tests associated with the study. Exclusion Criteria: 1. Presence of an immediately life threatening condition or disease other than heart failure, such as cancer, terminal renal failure etc. 2. Acute myocardial Infarction (MI), variant angina pectoris, unstable angina or acute coronary syndrome in the previous three months; 3. Previous stroke; 4. Coronary Artery Bypass Surgery (CABG) or Percutaneous Coronary Intervention in the past 3 months; 5. Episode of NYHA class IV heart failure, including acute pulmonary oedema in the previous three months; 6. Heart failure due to acute myocarditis. Restrictive or constrictive pericarditis, haemodynamically significant aortic valve insufficiency aortic stenosis, or mitral valve stenosis; 7. Severe renal or hepatic failure (Creatinine level>3 mg% (265 micromole/liter) or transaminase level four times ULN); 8. Diabetes Mellitus treated with insulin for more than two years prior to study entry; 9. Diabetic neuropathy; 10. Previous neck surgery, including for Peripheral Vascular Disease (PVD), malignancy, and previous irradiation therapy of the neck; 11. Current hypotension (systolic blood pressure below 80 mmHg); 12. Active peptic disease or history of upper GI bleeding; 13. Asthma, severe COPD (e.g. FEV1<1.5 liter), or severe restrictive lung disease; 14. 1st degree AV block with PR interval > 240msec, 2nd or 3rd degree AV block; 15. Atrial fibrillation or flutter in the in the previous 3 months; 16. Sustained ventricular tachyarrhythmia with hemodynamic compromise, in the absence of implanted ICD; 17. Long QT syndrome, congenital or acquired; 18. Recorded or suspected symptomatic vaso-vagal response; 19. Treatment by investigational drug or device within the past 3 months; 20. Glaucoma, or history of glaucoma; 21. Major psychiatric disorder in the present or in the past; Dementia; 22. Patients transplanted with tissues or organs; 23. Immunosuppressed patients; patients under systemic steroid treatment; 24. Anemia with Hb<10gr/L, unless treated with Epo; 25. Patients who are at risk for carotid arteries plaques and have unstable carotid plaques, as assessed by Echo Doppler; and/or patients with >70% carotid artery stenosis; 26. Patient is candidate for cardiac resynchronization device implantation. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Georg-August-Universität Göttingen | Göttingen | |
Germany | Otto von-Guericke University Clinik | Magdeburg | |
Germany | I. Medizinische Klinik, Klinikum Mannheim GmbH Universitätsklinikum Fakultät für klinische Medizin Mannheim der Universität Heidelberg | Mannheim | |
Italy | Fondazione IRCCS Policlinico "San Matteo" | Pavia | |
Netherlands | Academic Hospital Maastricht | Maastricht | |
Serbia | Pacemaker center, Cardiovascular institute Clinical Center of Serbia | Belgrade |
Lead Sponsor | Collaborator |
---|---|
BioControl Medical |
Germany, Italy, Netherlands, Serbia,
De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, Gavazzi A, Sanzo A, Dennert R, Kuschyk J, Raspopovic S, Klein H, Swedberg K, Schwartz PJ; CardioFit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promisin — View Citation
Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, Campana C, Revera M, Ajmone-Marsan N, Tavazzi L, Odero A. Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail. 2008 Sep;10(9 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The occurrence of all system and/or procedure related adverse events. | along the study | Yes | |
Secondary | Change in NYHA class | At 6-months | No | |
Secondary | Quality of Life | At 6-months | No | |
Secondary | Exercise capacity (by 6-min walk) | At 6-months | No | |
Secondary | LV Ejection fraction | At 6-months | No | |
Secondary | LV end-systolic and end-diastolic volumes | At 6-months | No | |
Secondary | Blood tests. | At 6-months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|